{
    "Trade/Device Name(s)": [
        "Calprest",
        "EasyCal"
    ],
    "Submitter Information": "Eurospital S.p.A.",
    "510(k) Number": "K191589",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130945"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "June 11, 2019",
    "Summary Letter Received Date": "June 14, 2019",
    "Submission Date": "June 11, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal Calprotectin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Extracted human stool"
    ],
    "Specimen Container(s)": [
        "EasyCal tube",
        "Primary stool container"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Colorimetric detection"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Accessory",
        "Extraction kit",
        "Tube"
    ],
    "Document Summary": "FDA 510(k) summary for Eurospital Calprest ELISA assay and EasyCal extraction device for quantitative measurement of fecal calprotectin to aid IBD diagnosis.",
    "Indications for Use Summary": "Quantitative ELISA for fecal calprotectin to aid in diagnosis of Inflammatory Bowel Diseases (IBD, Crohn\u2019s disease and ulcerative colitis) and to differentiate IBD from IBS in conjunction with other clinical and laboratory findings.",
    "fda_folder": "Immunology"
}